Shearman Mark S
Known title: EVP, Chief Scientific OfficerCIK: 0001643799
Associated companies
Transaction History
| EDIT | ▼ Sell | Open Market | 2,790 | $27K | 2/13/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 5,145 | $52K | 6/15/2022 | View on chart |
| EDIT | ▲ Buy | Grant | 31,709 | $0 | 2/10/2022 | View on chart |
| EDIT | ▲ Buy | Grant | 9,084 | $0 | 12/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Editas Medicine upgraded to Buy with $5 price target
Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.
Editas Medicine upgraded to Buy with $5 price target. Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.